Reichert Janice M, Dewitz Matthew C
Tufts University, Tufts Center for the Study of Drug Development, 192 South Street, Suite 550, Boston, Massachusetts 02111, USA.
Nat Rev Drug Discov. 2006 Mar;5(3):191-5. doi: 10.1038/nrd1987.
So far, most monoclonal antibodies have been developed for treating cancer or immunological diseases. However, the global spread of infections such as West Nile and corona viruses, and the need to address the potential threat of bioterrorism, has boosted public interest in, and government support of, counter-measures for infectious diseases. The attractive features of monoclonal antibodies, such as high specificity and effective recruitment of the immune system, would seem to make them excellent candidates as anti-infective agents. Here, we analyse trends in the development and approval of anti-infective monoclonal antibodies, and discuss factors that influence their success.
到目前为止，大多数单克隆抗体都是为治疗癌症或免疫疾病而研发的。然而，诸如西尼罗河病毒和冠状病毒等感染性疾病在全球的传播，以及应对生物恐怖主义潜在威胁的必要性，激发了公众对传染病应对措施的兴趣，并得到了政府的支持。单克隆抗体具有高特异性和有效激活免疫系统等吸引人的特性，这似乎使其成为抗感染药物的理想候选者。在此，我们分析了抗感染单克隆抗体的研发和获批趋势，并讨论了影响其成功的因素。
